Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Railway workers in Austria to strike Monday in pay standoff
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Railway workers in Austria to strike Monday in pay standoff
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Railway workers in Austria to strike Monday in pay standoff
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Railway workers in Austria to strike Monday in pay standoff
See how to make money instead of spending it on Black Friday with this offer (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Airbnb has a plan to fix cleaning fees
NASDAQ:OMCL

Omnicell - OMCL Stock Forecast, Price & News

$52.05
+1.00 (+1.96%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$51.00
$52.44
50-Day Range
$46.24
$92.98
52-Week Range
$46.19
$185.28
Volume
139,024 shs
Average Volume
990,355 shs
Market Capitalization
$2.31 billion
P/E Ratio
51.03
Dividend Yield
N/A
Price Target
$82.44

Omnicell MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
58.4% Upside
$82.44 Price Target
Short Interest
Bearish
7.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.50mentions of Omnicell in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-17.90%
From $1.62 to $1.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

348th out of 1,044 stocks

Electronic Computers Industry

4th out of 5 stocks

OMCL stock logo

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

Brokerages Set Omnicell, Inc. (NASDAQ:OMCL) PT at $75.43
Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut
Why Shares of Omnicell Dropped 33.6% This Week
Omnicell (OMCL) Q3 Earnings Top Estimates
Omnicell: Lack Of Earnings Upside Clamps Valuation
See More Headlines
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Company Calendar

Last Earnings
11/02/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/13/2023

Industry, Sector and Symbol

Industry
Electronic computers
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
3,800
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$82.44
High Stock Price Forecast
$157.00
Low Stock Price Forecast
$54.00
Forecasted Upside/Downside
+58.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$77.85 million
Pretax Margin
3.04%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$5.35 per share
Book Value
$25.64 per share

Miscellaneous

Free Float
43,067,000
Market Cap
$2.31 billion
Optionable
Optionable
Beta
1.01

Social Links


Key Executives

  • Mr. Randall A. LippsMr. Randall A. Lipps (Age 65)
    Founder, Exec. Chairman, Pres & CEO
    Comp: $2.44M
  • Mr. Peter J. KuipersMr. Peter J. Kuipers (Age 50)
    Exec. VP & CFO
    Comp: $1.18M
  • Ms. Christine MellonMs. Christine Mellon (Age 59)
    Exec. VP, Chief Admin. & People Officer
    Comp: $768.28k
  • Mr. Scott Peter SeidelmannMr. Scott Peter Seidelmann (Age 46)
    Exec. VP & Chief Commercial Officer
    Comp: $1.17M
  • Mr. Joseph Brian SpearsMr. Joseph Brian Spears (Age 62)
    Sr. VP, Chief Accounting Officer & Corp. Controller
  • Mr. Giri Chodavarapu
    Sr. VP & Chief Information Officer
  • Ms. Kathleen Nemeth
    Sr. VP of Investor Relations
  • Mr. Corey J. Manley
    Sr. VP & Chief Legal Officer
  • Ms. Roxanne Turner
    Sr. VP of Corp. Responsibility and Chief Compliance & Privacy Officer
  • Mr. Jorge R. Taborga (Age 63)
    Exec. VP of Engineering & Integration Management Officer













OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OMCL shares.
View OMCL analyst ratings
or view top-rated stocks.

What is Omnicell's stock price forecast for 2023?

8 brokers have issued twelve-month price targets for Omnicell's stock. Their OMCL share price forecasts range from $54.00 to $157.00. On average, they expect the company's share price to reach $82.44 in the next year. This suggests a possible upside of 58.4% from the stock's current price.
View analysts price targets for OMCL
or view top-rated stocks among Wall Street analysts.

How have OMCL shares performed in 2022?

Omnicell's stock was trading at $180.44 at the beginning of the year. Since then, OMCL stock has decreased by 71.2% and is now trading at $52.05.
View the best growth stocks for 2022 here
.

When is Omnicell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our OMCL earnings forecast
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its earnings results on Tuesday, November, 2nd. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.63 by $0.45. The business had revenue of $296.40 million for the quarter, compared to the consensus estimate of $283.82 million. Omnicell had a net margin of 3.67% and a trailing twelve-month return on equity of 9.74%. During the same quarter in the prior year, the firm posted $0.40 earnings per share.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its fourth quarter 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $0.05-$0.15 for the period, compared to the consensus earnings per share estimate of $1.21. The company issued revenue guidance of $285.00 million-$295.00 million, compared to the consensus revenue estimate of $382.33 million.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.67%), Conestoga Capital Advisors LLC (3.77%), Macquarie Group Ltd. (2.73%), Lazard Asset Management LLC (2.48%), Geneva Capital Management LLC (2.18%) and Dimensional Fund Advisors LP (1.81%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $52.05.

How much money does Omnicell make?

Omnicell (NASDAQ:OMCL) has a market capitalization of $2.31 billion and generates $1.13 billion in revenue each year. The company earns $77.85 million in net income (profit) each year or $1.02 on an earnings per share basis.

How many employees does Omnicell have?

The company employs 3,800 workers across the globe.

Does Omnicell have any subsidiaries?
The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.
Read More
How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (650) 251-6100, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 11/27/2022 by MarketBeat.com Staff